Spring direct naar de hoofdnavigatie of de inhoud
‘There may be more to an invention than meets the eye. By recording the invention in a patent application, this added value comes into its own.’
Raygene Martier

Raygene Martier

  • Life Sciences
  • Trainee Patent Attorney

Raygene Martier studied  Biomolecular Sciences  at VU Amsterdam with majors in molecular biology and  biochemistry. He gained work experience in both academia and industry.

Continue reading

He  has extended his  knowledge in areas such as gene therapy, neurology,  virology, microbiology, immunology, biochemistry, molecular biology, cell biology, diagnostics and medical biotechnology. He started his PhD in 2015 at the gene therapy company uniQure,  where he was responsible for development of RNAi-based gene therapies for differed neurodegenerative disorders. Here he also had the opportunity to support the IP department and became aware that R&D and IP go hand in hand.

Raygene  joined V.O. in 2019 as trainee patent attorney. He enjoys  being at the interface between science and Patent Law.

Education

  • PhD in RNAi-based gene therapies for  neurodegenerative disorders, Leiden U niversity/uniQure (2020)
  • MSc in Biomolecular Sciences, VU Amsterdam (2013)
  • BSc in Biotechnologie, Noordelijke Hogeschool Leeuwarden (2009)

Publications

  • Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, Konstantinova P. (2019). Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol. Ther. Nucleic. Acids.14: 593-608.
  • Martier R, Liefhebber JM, Garcia-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, Konstantinova P. (2019). Targeting RNA-Mediated toxicity in C9orf72 ALS and/or FTD by RNAi-Based gene Therapy. Mol. Ther. Nucleic. Acids.16: 26-37
  • Martier R, Sogorb Gonzalez M, Stricker-Shaver J, Hübener-Schmid J, Keskin S, Witjas J, van Deventer SJ, Konstantinova P, Phuc Nguyen H, Evers MM. (2019). Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease. Mol. Ther. Methods & Clinical Development Acids. https://doi.org/10.1016/j.omtm.2019.10.008.
  • Pietersz KL, Martier R, Baatje SM, Liefhebber JM, Brouwers CC, Pouw SM, Fokkert L, Lubelski J, Petry H, Martens GJM, van Deventer SJ, Konstantinova P, Blits B. (2019). Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery. Gene Ther. Under submission.
  • Liefhebber, J., Martier, R., Van der Zon, T., Keskin, S., Huseinovic, A., Lubelski, J., Blits, B., Petry, H., Konstantinova, P. (2019) In depth characterization of a Mifepristone regulated expression system for AAV5-mediated gene therapy in the liver. Mol. Ther. Methods & Clinical Development.13: 512-525.
  • Keskin S, Brouwers CC, Sogorb-Gonzalez M, Martier R, Depla JA, Vallès A, van Deventer SJ, Konstantinova P, Evers MM. (2019) AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patientderived neuronal cultures and astrocytes. Mol. Ther: Methods & Clinical Development. doi: https://doi.org/10.1016/j.omtm.2019.09.010.
  • Miniarikova J, Zimmer V, Martier R, Brouwers C. C, Pythoud C, Richetin K, Konstantinova P. (2017). AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease. Gene Ther. 24: 630-639.
  • Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Konstantinova P. (2016). Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington’s Disease. Mol. Ther. Nucleic Acids: e297.
  • MacZuga P, Verheij J, Van Der Loos C, Van Logtenstein R, Hooijer G, Martier R, Konstantinova P. (2014). Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver. Gene. Ther. 21: 60-70.
  • Staszewski O, Baker RE, Ucher AJ, Martier R, Stavnezer J, Guikema JEJ. (2011). Activation-Induced Cytidine Deaminase Induces Reproducible DNA Breaks at Many Non-Ig Loci in Activated B Cells. Molecular Cell. 41(2): 232-242.

Languages

  • Dutch
  • English
  • Spanish
  • Papiamento

Also see these experts

Marijke Westra

Marijke Westra

  • European and Dutch Patent Attorney
  • Associate
Saskia van Doorn

Saskia van Doorn

  • European and Dutch Patent Attorney
  • Senior Associate
More experts

News

Well-prepared for the future

Column by Cees Jansen, former chairman V.O. After 26 years, I have left V.O. I was chairman for the last 12 years, a task that I have passed on to Herman Witmans. This is a good moment to look back.Continue reading

Recommended by JUVE Patent

In May 2020, V.O. was recommended by JUVE Patent in the categories Patent Filing and Prosecution. Listed as recommended individuals are Marco Box, Leo Jessen, Bernard Ledeboer, Otto Oudshoorn and Jetze Beeksma.Continue reading

Two prizes for V.O.

This January, the Netherlands’ office of V.O. was crowned the best patent firm of 2019. This selection as the ‘Netherlands Patent Attorney Firm of the Year’ was announced by the Intellectual Asset Management (IAM) and World Trademark Review (WTR).Continue reading

Events

Knowledge for Growth 2020

Don’t miss the 2020 digital edition on 9 and 10 September and capture the attention of 1,200 high-level life sciences actors from about 550 companies & organisations! The cream of the European life sciences community will be participating in the 16th edition of flanders.bio’s annual knowledge for growth business conference, attracting decision makers from biotech, pharma and medtech as well as investors, universities, topnotch research institutes, policymakers and competence providers. Continue reading

Sustainable Plastics & Materials Expo 2020

ATLAS Theater, Raadhuisplein 100, Emmen, Netherlands

The first edition of the Sustainable Plastics & Materials Expo 2020 will take place in Chemical Cluster Emmen in the Netherlands. Continue reading

IP Service World 2020

Holiday Inn Munich - City Centre, Hochstraße, München, Germany

Europe’s largest IP Convention & Trade Fair, the IP Service World, is a very unique event. It is the perfect mixture of a comprehensive trade fair and a top-class convention with contributions from leading experts. Continue reading